Hepatic histomorphological and biochemical changes following highly active antiretroviral therapy in an experimental animal model: Does Hypoxis hemerocallidea exacerbate hepatic injury?  by Azu, Onyemaechi Okpara et al.
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As  the  roll-out  of  antiretroviral  therapy  continues  to drive  downwards  morbidity  and  mortality  in  people
living  with  HIV/AIDS  (PLWHAs),  organ  toxicities  (especially  the  liver)  are  frequently  becoming  a  major
concern  for  researchers,  scientists  and healthcare  planners.
This  study  was  conducted  to  investigate  the  possible  protective  effect  of  Hypoxis  hemerocallidea  (AP)
against  highly  active  antiretroviral  therapy  (HAART)-induced  hepatotoxicity.  A total  of  63  pathogen-free
adult  male  Sprague-Dawley  rats  were  divided  into  9 groups  and  treated  according  to  protocols.
While  no  mortality  was  reported,  animals  treated  with  adjuvant  HAART  and  AP recorded  least%  body
weight  gain.  Signiﬁcant  derangements  in serum  lipid  proﬁles  were  exacerbated  by treatment  of  with
AP  as LDL  (increased  p  < 0.03),  triglycerides  (increased  p  < 0.03)  with  no change  in  total  cholesterol  lev-
els.  Adjuvant  AP  with  HAART  caused  reduction  in  LDL  (p  <  0.05  and  0.03),  increased  HDL  (p  <  0.05)  and
TG  (p <  0.05  and  0.001  for  AP100 and  AP200 doses  respectively).  Markers  of  liver  injury assayed  showed
signiﬁcant  increase  (p  <  0.003,  0.001)  in  AST  in  AP  alone  as  well  as HAART+  vitamins  C  and  E groups
respectively.  Adjuvant  HAART  and  AP  and  vitamins  C  and  E also caused  signiﬁcant  declines  in ALT  and
ALP  levels.  Serum  GGT  was  not  markedly  altered.  Disturbances  in histopathology  ranged  from  severe
hepatocellular  distortions,  necrosis  and  massive  ﬁbrosis  following  co-treatment  of  HAART  with  vitamins
C and  E  as  well  as  HAART  alone.  These  results  warrant  caution  on the  adjuvant  use  of AP with  HAART  by
PLWHAs  as  implications  for hepatocellular  injuries  are  suspect  with  untoward  cardiometabolic  changes.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).. Introduction
The acquired immuno-deﬁciency syndrome (AIDS) is a signiﬁ-
ant threat to the health of mankind and the search for effective
herapies to treat AIDS is of paramount importance. The devel-
pment and evolution of therapy against the human immune
eﬁciency virus (HIV) therapy (which causes AIDS), has tremen-
ously improved over the last 2 decades with resultant signiﬁcant
ncrease in life expectancy among HIV-infected patients [1,2].
ighly active antiretroviral therapy (HAART), a combination of
his chemotherapeutic regime for people living with HIV/AIDS
∗ Corresponding author. Fax: +27 312604080.
E-mail addresses: azu@ukzn.ac.za, amechi2@yahoo.com (O.O. Azu).
ttp://dx.doi.org/10.1016/j.toxrep.2015.12.013
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access (PLWHAs), suppresses viral replication but its major drawback is
adverse effects of toxicities to organs [2].
Hepatotoxicity has been associated with most antiretroviral
drugs like Zidovudine, Stavudine or Didanosine [3] and potentially
contributes in part to poor compliance and adherence necessi-
tating switch with therapy [2]. The liver performs the function
of formation of excretory products, degradation of complex cel-
lular materials, and the synthesis of plasma proteins. Due to
this functional complexity, any change in liver function and his-
toarchitecture becomes an important consideration for study of
abnormality [4].Besides the high cost of HAART regimens, the adverse effects
associated with using chemotherapy for the treatment of HIV infec-
tion have further encouraged the utilization of herbal medicines as
an alternative medical therapy by PLWHAs [5]. This complemen-
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ary or alternative therapy is thought to mitigate this toxic effect of
AART regimens.
Hypoxis hemerocallidea commonly known as African potato (AP),
lso known as Hypoxis rooperi (Hypoxidaceae), has a long history
f traditional use for a diversity of ailments [6] and more recently
as been the subject of several scientiﬁc studies. In many parts
f Africa, the corms of this attractive yellow ﬂowered herb have
een used in the treatment of urinary diseases, prostate hyper-
rophy and cancer [7] and more recently as immune boosters for
IV–AIDS. Its traditional usage dates back many generations [8]
nd anecdotal evidence indicates that the plant can be poisonous
9]. The AP is noted for the occurrence of a hypoxoside, which
s a secondary metabolite of the plant [7] that is hydrolyzed into
ooperol in vivo—the active and powerful antioxidant component
f the corm [10] in the large intestine.
Pharmacokinetic studies have indicated that rooperol can be
ound in feces, and metabolites are found in the serum and urine as
ts glycosides, sulfates, mixed glucuronides, and sulfuronides [11].
hese metabolites, when conjugated back to rooperol, were found
o be cytotoxic to cancerous cells [7]. The glycoside has low toxicity
nd the corm containing it is also used as food [6] and has been well
sed for traditional and pharmaceutical purposes [8].
With increasing interest in the use of phytosterols (one of phyto-
hemical components of AP) for the reduction of serum cholesterol
nd for immune boosting, there has been a resultant increase in
cientiﬁc investigations [12] surrounding these beneﬁts. Interest-
ngly, there has been a surge in commercially available herbal
edicines containing sterols with AP extract enrichments claimed
o be efﬁcacious against a variety of diseases. However, the scien-
iﬁc validation of these claims remains to be veriﬁed despite its
nti-inﬂammatory, antimicrobial, antidiabetic, anticonvulsant and
nticancer properties reported by various authors [13–15] but none
n any antiretroviral-based therapy. As a result, there is paucity of
iterature explaining its attenuating inﬂuence on liver associated
ith HAART.
Therefore, we investigate the role of crude aqueous extracts of
. hemerocallidea (AP) on the histoarchitecture of the liver, glyco-
en distribution, degree of ﬁbrosis and hepatocellular functional
ndexes of animal experimental protocol following HAART.
. Materials and methods
.1. Chemicals/drugs
Lamivudine (3TC), Stavudine and Nevirapine (Aspen) and vita-
in  C (L-ascorbic acid) were procured from Pharmacare Ltd, Port
lizabeth, South Africa and are of analytical grade. Vitamin E
olution was obtained from Kyron Prescription CC, Benrose in
ohannesburg.
.2. Plant
Fresh corms of AP were purchased from a local ‘Muthi’ shop in
mbilo Road, Durban, KwaZulu-Natal, between June and July, 2014.
he corms were authenticated at the Department of Life Science,
estville Campus, University of KwaZulu-Natal, South Africa.
.3. Preparation of corm aqueous extract
AP fresh corms were extracted according to the procedure of
jewole et al. [16]. They were washed with water, cut into smaller
ieces, air dried at room temperature (25–28 ◦C) and ground into
owdered form in a commercial blender. The milled corm (250 g)
as soaked in hot distilled water and extracted twice, on each
ccasion with 2.5 L of hot distilled water (at 90–100 ◦C) for 12 h.
he combined extract soluble were concentrated to dryness underorts 3 (2016) 114–122 115
reduced pressure in a rotary evaporator at 70 ± 1 ◦C. The result-
ing crude aqueous extract was  freeze dried, ﬁnally giving of a dark
brown, and powdery aqueous extract residue. Without any further
puriﬁcation, aliquot portions of the aqueous extract residue were
weighed and dissolved in distilled water (at room temperature) for
use on each day of our experiments.
2.4. Ethics approval, animal treatment and experimental design
Sixty three pathogen-free adult male Sprague-Dawley rats (aged
9–10 weeks old) and weighing between 256 and 312 g were used
for this study. The animals were bred and maintained at the Animal
House of the Biomedical Resources Unit, University of KwaZulu-
Natal. The animals received humane care in accordance with
the Principle of Laboratory Animal Care of the National Medical
Research Council and the Guide for the Care and Use  of Laboratory
Animals of the National Academy of Sciences (National Institute
of Health Guide, 1985). The study protocol was  approved by the
University of KwaZulu Natal Animal Ethics Committee (Ethics
clearance number: 100/14/Animals). All the rats were housed in
well ventilated plastic cages (2 rats per cage) having dimensions
of (30 cm long × 20 cm wide and 13 cm high). They were main-
tained under standardized animal house conditions (temperature:
21–23 ◦C; light: approximately 12 h light per day) and were fed
with standard rat pellets (from Meadow feeds a Division of Astral
Operations Limited, Durban, South Africa) and given tap water ad
libitum. The animals were randomly distributed to nine treatment
groups; A, B, C, D, E, F, G, H and I and treated as indicated below.
Group A: HAART (a cocktail of Lamivudine, Stavudine and
Nevirapine) using recommended human therapeutic doses and
accordingly adjusted to the equivalent animal dose (stavudine 0.57,
lamivudine 2.06 and nevirapine 1.54 mg/kg body weight respec-
tively).
Group B: received HAART and AP (100 mg/kg body weight)
Group C received HAART and AP (200 mg/kg body weight)
Group D received HAART and Vitamin C (250 mg/kg body
weight)
Group E received HAART and Vitamin E 40 mg/kg body weight
[17]
Group F: Combination of HAART, Vitamins C and E.
Groups G and H received AP extract alone at doses of 100 and
200 mg/kg respectively.
Groups I served as the control administered 0.9% normal saline.
All administration was  done daily by oro-gastric gavage except
for vitamin E which was  administered subcutaneously. At the end
of the treatment period (56 days), the animals were killed 24 hours
after the last treatment under excess Halothane® anesthesia.
2.5. Body and liver weight
Body weights of animals were recorded on the ﬁrst day before
treatment (initial), thereafter weekly and on the day of sacriﬁce
(ﬁnal). Liver weight (LW) was measured by an electronic balance
(Mettler Toledo; Microsep (Pty) Ltd, Greifensee, Switzerland).
2.6. Assessment of liver function and lipid proﬁle
Blood samples were collected through cardiac puncture and
allowed to cloth for 30 min  and centrifuged for 15 min  at 3000 rev-
olutions per minute. The serum was decanted into Eppendorf tubes
and prepared for biochemical analyses.
Biochemical analyses of the serum enzymes for alanine
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline
phosphatase (ALP) and gamma-glutamyl transferase (GGT) were
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pectrophotometrically determined by the method of Reitman and
rankel [18].
.7. Determination of serum lipids
Low density lipoprotein (LDL), high density lipoprotein (HDL),
riglycerides (TG) and total cholesterol (CHOL) were determined by
nzymatic methods according to Diniz et al. [19] using commercial
iagnostic kits (Randox, UK).
.8. Histopathological examination of liver tissues
Twenty four hours after the last treatment the animals were
uthanized under excess Halothane® anesthesia and the liver
issues were excised, blotted of blood and weighed. They were
xamined for gross pathology and immediately ﬁxed in 10% Neutral
uffered formalin. After proper ﬁxation, the tissues were dehy-
rated in graded series of alcohol, cleared in Xylene and embedded
n parafﬁn wax using a cassette.
For routine histological study, the liver tissues were sectioned
t 5 m thickness using Leica RM 2255 microtome and stained
ith hematoxylin and eosin (H&E) for general assessment of liver
tructure. For histochemical studies, the tissues were stained with
eriodic acid Schiff’ (PAS) for glycogen, neutral polysaccharides and
asement membrane, and Masson trichrome (MT) for the assess-
ent of possible liver ﬁbrous architecture [20]. The stained slides
ere then cover slipped using DPX mounting glue directly over the
issue section ensuring no air bubbles were trapped. Thereafter,
he slides were left overnight to dry for examination under light
icroscope.
The sections were examined using a binocular microscope and
mage acquired using the Nikon Eclipse 80i (Tokyo, Japan). An inde-
endent Histopathologist blinded to the treatment groups reported
n the qualitative assessments of the slides.
.9. Statistical analysis
Continuous variables (liver and body weights, liver function
est and lipid proﬁle level), were analyzed by one-way analysis
f variance (ANOVA) followed by Dunnett’s multiple comparison
ost-test using Graph pad prism® statistical software 6.02. The
esults are expressed as mean ± SD (standard deviation). Values
ere considered signiﬁcant at p < 0.05.
. Results
.1. Body weight and organ (liver) weight changes
While the ﬁnal body weight of animals in all groups were
igher than their corresponding initial body weight, the percent-
ge weight gain was maximal in group D (HAART with vitamin
), then groups H and G all recording 48.66%, 46.38% and 44.08%
espectively. Least percentage weight gain was observed in animals
reated with HAART + AP 100 mg/kg (29.89%) (Table 1). There was  a
igniﬁcant decline in ﬁnal body weight in groups C and F (p < 0.05),
 and H (p < 0.03) when compared with control. There were no
igniﬁcant (p > 0.05) increase in liver weight in group A compared
ith the control. Group F recorded the lowest liver weight when
ompared with the control (p < 0.03). Similarly, organ-body weight
atios were signiﬁcantly decreased in groups B, C, E (p < 0.05), D and
 (p < 0.03) (Table 1)..2. Serum AST, ALT, ALP and GGT in the experimental study
There were changes in the functional hepatotoxicity indices
ecorded via AST, ALT ALP and GGT. AST levels were reduced inorts 3 (2016) 114–122
groups A and E (not signiﬁcant) when compared with the con-
trol, it was  signiﬁcantly elevated in groups F and H (HAART with
vitamin C&E/AP 200 mg/kg) respectively (p < 0.001, 0.03) compared
with the control. There was statistically signiﬁcant decrease in ALT
levels in groups A–E (p < 0.03) whereas the levels in groups F, G
and H were lower than that of control (p > 0.05). Similarly, ALP lev-
els of animals treated with HAART, HAART + AP (both doses), and
HAART + vitamin E (p < 0.001), HAART + vitamin C, AP (both does)
(p < 0.03) were signiﬁcantly lower compared with the control. The
results of the GGT levels were not statistically signiﬁcant in all
groups when compared with the control group (p > 0.05) (Table 2).
3.3. Effect on lipid proﬁle following treatment with HAART and AP
Although total cholesterol levels in all groups were slightly
higher than control values, these were not signiﬁcantly different
(p > 0.05). There were statistically signiﬁcant increase in the serum
levels of LDL in groups F and H (p < 0.03), whereas groups treated
with HAART, HAART + vitamin C (p < 0.001), HAART + AP100 mg/kg,
HAART + vitamin E (p < 0.05) as well as HAART + AP200 mg/kg
(p < 0.03) all recorded signiﬁcant decline in the parameter com-
pared with the controls. HDL levels in groups A, C, E (p < 0.05) as
well as in groups D, F and H (p < 0.03) were all signiﬁcantly lower
than the control group. While triglyceride (TG) levels in groups A, C,
D, E (p < 0.001), B (p < 0.05) statistically declined, levels were how-
ever increased in the groups administered HAART + vitamins C and
E (p < 0.001) as well as AP200 mg/kg (p < 0.03) (Table 3).
3.4. Histopathology of liver sections (H&E, Masson’trichrome
and PAS techniques)
In H&E stained slides, control sections of liver showed typical
hepatocellular architecture with central vein (containing blood)
and cords of hepatocytes arranged peripherally in a radiating fash-
ion. The outlines of hepatocytes and sinusoidal spaces are clearly
seen with no obvious pathologies. This trend was observed in
liver sections from groups E (HAART + vitamin E). Histopathological
assessment of other groups revealed various degree of distortions.
Liver tissues of group B animals showed mild distortion in the radial
arrangements of hepatocytes and sinusoids with some form of bal-
looning of hepatocytes. Whereas in group C rats, some of the central
veins appeared eroded with gradual loss of polyhedral arrangement
of cords of cells. There was  extensive necrosis of hepatocytes and
sinusoidal spaces with marked loss of architecture in group D sec-
tions of liver. Some of the hepatocyte nuclei appeared enlarged.
In sections of liver of group F animals, there was complete loss of
architecture with hepatocytes appearing as isolated cell with (or
without) prominent nucleoli. Groups treated with AP alone (both
doses) showed liver sections that generally appeared enlarged in
sinusoidal appearance with necrotic distortions (Fig. 1).
PAS-stained sections reveal glycogen presence in the tissues and
is depicted by pink color in the sections. Liver tissues from groups
F, G, D, A, H, E, B and C showed decreasing PAS-staining intensity
respectively with HAART + vitamins C and E treated groups hav-
ing the maximum staining whereas HAART + AP200 mg/kg the least
compared with controls. The extensive and generalized staining in
slides F, G, D revealed large amount of glycogen in hepatocytes as
well as in cords/sinusoidal spaces with bright pink hepatocytes,
neutral polysaccharides and basement membranes completely
PAS-positive in the sections. While the PAS stain demonstrates
glycogen, indications for distortion in hepatocellular cords were
evident in the grading of the intensity as well (Fig. 2).Masson’s trichrome stains ﬁbrous tissue blue while the cyto-
plasm of hepatocytes are stained red and nuclei could be dark or
red as well. Sections of liver in control group showed normal red-
stained hepatocytes and ﬁbrous elements that are lightly stained
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Table  1
Body and liver weight changes in experimental groups.
Group Treatment Initial (g) Final (g) BW diff (g) % BW diff LW (g) LBWR
A HAART 285.86 ± 3.80 407.29 ± 13.69 115·57 37·11 14.18 ± 3.41 0.035
B  HAART + AP1 311.43 ± 3.56 427.00 ± 09.94 83·57 29·89 12.05 ± 1.49 0.028*
C  HAART + AP2 279.57± .16 363.14 ± 11.50** 101·14 35·92 10.05 ± 0.98* 0.028*
D  HAART + vit C 281.57 ± 2.88 382.71 ± 05.51 127·00 48·66 10.08 ± 0.76* 0.026**
E  HAART + vit E 261.00 ± 7.49 388.00 ± 08.28 88·14 32·46 10.66 ± 0.72* 0.027*
F  HAART + C + E 271.57 ± 7.14 359.71 ± 12.31** 98·86 36·21 09.41 ± 1.27** 0.026**
G  AP1 273.00 ± 6.29 371.86 ± 18.43* 113·15 44·08 13.16 ± 2.38 0.035
H  AP2 256.71 ± 8.65 369.86 ± 12.66* 121·00 46·38 12.83 ± 1.31 0.035
I  Control 260.00 ± 6.06 381.00 ± 11.21 121·43 42·48 13.78 ± 1.06 0.036
*p < 0.05; **p  < 0.03 compared with control; BW = body weight of rats, LW = liver weight of rats, LBWR = liver-body weight ratio; AP1/AP2-100 and 200 mg/kg dosage.
Table  2
Effect on serum AST, ALT ALP and GGT following treatment with HAART and AP.
Group AST (IU/L) ALT (IU/L) AST/ALT ratio ALP (IU/L) GGT  (IU/L)
A 92.00 ± 3.23 48.67 ± 11.91*** 1.89 116.67 ± 41.55*** 2.00 ± 0.89
B  106.33 ± 7.45 52.00 ± 2.37*** 2.04 95.00 ± 5.59*** 3.00 ± 0.00
C  108.00 ± 9.30 51.33 ± 8.96*** 2.10 88.00 ± 4.98*** 3.00 ± 0.89
D  104.67 ± 4.03 55.33 ± 7.61*** 1.89 122.67 ±16.79** 3.33 ± 0.52
E  94.33 ± 13.55 44.00 ± 3.10*** 2.14 99.67 ± 4.03*** 3.00 ± 0.89
F  128.33 ± 6.83*** 75.67 ± 17.6 1.70 167.00 ± 5.87 2.67 ± 0.52
G  105.33 ± 11.67 75.00 ± 8.53 1.40 160.67 ± 36.88* 3.00 ± 0.89
H  116.00 ± 13.00** 75.67 ± 8.31 1.53 145.33 ± 23.62** 2.67 ± 1.37
I  96.33 ± 9.48 79.67 ± 9.97 1.21 218.00 ± 71.52 2.33 ± 0.52
*p < 0.05, **p < 0.03, ***p < 0.001 compared with control, AST = alanineamino aspartate, A
transferase.
Table  3
Lipid proﬁle in experimental groups.
Group LDL (mmol/L) HDL (mmol/L) CHOL (mmol/L) TG (mmol/L)
A −0.10 ± 0.02*** 1.00 ± 0.05* 1.10 ± 0.09 0.45 ± 0.09***
B  −0.23 ± 0.13* 0.94 ± 0.06 1.07 ± 0.14 0.68 ± 0.16*
C  −0.12 ± 0.09** 0.98 ± 0.03* 1.10 ± 0.09 0.52 ± 0.13***
D  −0.09 ± 0.06*** 1.04 ± 0.11** 1.17 ± 0.14 0.45 ± 0.14***
E  −0.17 ± 0.03* 0.97 ± 0.05* 1.03 ± 0.05 0.51 ± 0.04***
F  −0.62 ± 0.01** 1.06 ± 0.05** 1.13 ± 0.05 1.50 ± 0.04***
G  −0.27 ± 0.03 0.92 ± 0.05 1.07 ± 0.05 0.90 ± 0.01
H  −0.63 ± 0.13** 1.06 ± 0.06** 1.07 ± 0.05 1.39 ± 0.30**
I  −0.38 ± 0.17 0.67 ± 0.47 1.03 ± 0.14 1.03 ± 0.23
*
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ein,  HDL = high density lipoprotein, CHOL = total cholesterol, TG = triglycerides.
lue especially around the central vein. Photomicrographs from
iver tissues of groups treated with HAART + vitamins C + E as well
s HAART alone showed extensive network of blue-stained ﬁbrous
omponents in a necrotized, disorganized hepatic tissue cord. In
roups B–E, there were ﬁne threads of blue-stained central veins
nd thin ﬁbers across the cords. In many tissue sections, the central
eins were well highlighted in their ﬁbrous content and hepato-
ytes deeply stained (Fig. 3).
. Discussion
As the roll-out of antiretroviral therapy continues to drive
ownwards morbidity and mortality in PLWHAs, organ toxicities
especially the liver) are frequently becoming a major concern
or researchers, scientist and healthcare providers. Our current
tudy revealed that the administration of HAART and H. heme-
ocallidea (AP) showed various perturbations in histological and
iochemical indices which brings to attention the potential pit-
alls in this adjuvant therapy. Due to the livers’ central role
n the clearance and transformation of chemicals it is exposed
o toxic injuries [21,22]. In this study, organ-body weight ratio
ffers insight on toxicity/or inﬂammation [23] and whilst there
ere signiﬁcant liver-body weight ratios especially in HAART withLT = alanine aminotransferase, ALP = alkalinephosphatase, GGT = gamma-glutamyl
adjuvant AP/vitamins groups, these reductions may be attributed
to cellular morphological changes and tissue movements [24].
Hepatomegaly has been noted with HAART, drawing caution
on possible implications with individuals with co-existing liver
pathologies.
Repeated oral administration of HAART and AP caused an
increase in body weight of experimental animals mostly marked
in HAART+ vitamin C group. While weight gain may be associated
with the initiation of HAART possibly due to other metabolic issues
related to lipid/sugar, the long term consequence is eventual weight
loss [25]. Our results suggests that extracts of AP slowed the weight-
gaining potential of the antiretroviral regimen as depicted in the
results. The overall implication of this remains to be interpreted
in the context of other results assessed. However, it is known that
nucleotide reverse transcriptase inhibitors e.g., AZT (used in the
cocktail) decreases the activity of cytochrome c oxidase and fatty
acid synthase with consequent reduction in cellular lipid accumu-
lation [26].
We assayed serum alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST), alkaline phosphatase (ALP) and
gamma-glutamyl transferase (GGT) in this protocol. Serum ALT
and AST are helpful in understanding inﬂammatory and necrotic
changes in the liver [27]. The increased levels of AST (especially
following adjuvant HAART with AP/vitamins C and E) in our work
supports previous reports by Oviosu et al. [25] on effects of AZT and
nevirapine on liver enzymes. While the levels of ALT were reduced
in our study, AST levels were on the higher level. Elevation in the
level of amino transferases are associated with the commencement
of antiretroviral therapy in humans [28] and can be exacerbated
by other co-infections like hepatitis B or C virus [28–30]. The high
concentration of both amino transferases implies that increased
activities reﬂects a major permeability problem or cell disruptions
in the liver [31].
In the quest for better outcome and well-being of PLWHAs, there
is increased utilization of alternative and complimentary medicines
in association with HAART, although many of these adjuvants have
been implicated in drug-induced liver/other organs’ injury [32].
AP alone at both doses showed a tendency to cause appreciable
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[ig. 1. (A–I) Photomicrographs of liver sections stained with H & E. Note the norma
here  are various degrees of distortion (mild to severe) in the radial arrangement o
.
ncrease in values of liver enzymes compared with HAART and
itamins C and E. This may  contribute to perturbations in liver
etabolism in addition to HAART which ultimately may  predis-
ose to worsened outcomes, unfortunately. We  did observe that
LP levels were mostly reduced in our study (even in HAART alone
roups). Discordant outcomes have been seen also in the work of
ayode et al. [33]. Again, elevations in these enzymes is a sensi-
ive signal for liver injury but may  not be speciﬁc or even relevant
linically as most of these elevations does improve with duration
30].tecture of hepatocellular cords sinusoidal spaces and central vein in groups E and I.
tic cords seen in groups B–D. extensive necrosis are observed in groups F, H, A and
Evidence that patients with high levels of AST or ALT had a
ﬁve-fold greater risk of ﬁbrosis or cirrhosis than in patients with
lower enzyme levels still remains an unresolved issue. Studies
investigating the link between antiretroviral therapy, HIV and hep-
atitis C co-infection [34] showed no links with hepatic ﬁbrosis in
persons treated with ART. Histopathological assessments revealed
that in HAART-treated groups as well as HAART with vitamins C
and E, there were extensive network of ﬁbrous connective tissue
which dominates the disorganized architecture. Moderate ﬁbrotic
strands were also observed following adjuvant treatment with AP.
O.O. Azu et al. / Toxicology Reports 3 (2016) 114–122 119
F  pink 
o  H.
T
i
i
ﬁ
a
v
t
c
lig. 2. (A–I) Photomicrographs of liver sections stained with PAS. Note the intense
rder.  There is hepatocellular cord derangements seen mostly in groups A, F, G and
herefore, although the argument that ART causes chronic histolog-
cal liver disease, we support that long term liver enzyme elevation
n addition to other positive indices tilts the balance towards liver
brosis as supported by Qurishi et al. [35]. These perturbations
re unlikely to be mitigated by AP or concomitant treatment with
itamins C and E.
Lipid proﬁle assessment (composite of total cholesterol—TC,
riglycerides—TG, and lipoproteins (high HDL) and (low LDL) play
ritical role in enabling evaluation of cardiovascular outcomes fol-
owing ART. AP appeared to show diverse actions on lipoproteinscolour and intensity of hepatocytes in groups F, G, D, A, H, E, B and C in decreasing
with adjuvant use with HAART promoting HDL and lowering LDL
and TGs but with no overall effect on cholesterol. On the con-
trary, AP (higher dose) seemed to execute the reverse effects on
the above parameters. These discordances remains to be further
clariﬁed but may  not be unconnected with the possibility that
herb–drug interactions in the former could favor a better outcome
whereas a single herb administration is actually perilous on these
lipid proﬁle markers in this protocol. We  correlated these observa-
tions with the PAS-staining intensities of liver sections and there
is supporting link. Groups H (AP200mg/kg), E (HAART + vitamin E), B
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tig. 3. (A–I) Photomicrograph of the liver sections stained with Masson Trichrome
e  seen as dark red to black structures within cells and ﬁbrous elements stained li
assive ﬁbrosis in groups A, F, G and H.
HAART + AP100mg/kg) and C (HAART +AP200mg/kg) showed the least
AS-staining intensity possibly indicating low deposits of glycogen.
hese derangements in lipid and glucose metabolism are supported
y previous studies (RCT [37]) involving non-NRTIs in regimen but
ay  also be due to other contributory factors like gender and age
mong others [37].
It is interesting to note that while AP extracts upregulated the
evels of LDL and TG, these parameters were lowered when AP was
sed as adjuvant to HAART. Also, adjuvant use of vitamins C and
 upregulated HDL and lowered TG with no signiﬁcant change in
otal cholesterol. These opposite effects on lipid proﬁles alludes to Note the normal architecture of the liver with hepatocytes stained red, nuclei can
ue in colour in the control group. There is extensive necrosis of hepatic cords and
H&E stained sections of the liver where vitamin E showed good
cyto-protective effects and adjuvant use of vitamins C and E with
HAART was  seen to exacerbate hepatic cellular structural injury.
These observations agrees with our previous work [23] and are
suggestive that the pharmacokinetic interactions between ART and
plant-based extracts can adversely alter lipid/lipoprotein levels and
may augment the risk for cardiometabolic syndrome.Whether there is possibility of antiretroviral sequestration/or
boosting in hepatic tissues, the exact mechanistic pathway for the
negative indices triggered by AP in our study is still a subject
for further interrogation. However, the pathogenic pathway for
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AART-mediated injury has been associated with mitochondrial
oxicity especially with NRTIs [36,37]. Inhibition of gamma-
olymerase is linked with damage to mitochondrial DNA which
ffects all other organs including the liver [37]. We  did not report
hanges in intracellular glutathione reserve (a major antioxidant
efense that protects against toxic insults), it is reasonable to
elieve that a perturbed antioxidant system could perhaps be a con-
ributory arm towards the inability of AP to mitigate the ravages of
AART in our study.
. Conclusions
While HAART continues to be fundamental in the management
f HIV/AIDS in sub-Saharan Africa, the complex issues of toxici-
ies, resistance as well as herbal-drug interactions would continue
o be hindrance to achieving the desirable goals. It has emerged
rom this study that hepatic injuries and perturbations emanating
rom HAART were not mitigated by AP adjuvants both seen in the
istopathological and biochemical assessments. There is no merit
n concomitant use of vitamins C and E with HAART also based on
he negative outcomes. Therefore, caution is warranted following
he over-the-counter use of AP extracts by PLWHAs as immune
ooster as possibility of exacerbation of hepatic injuries are high.
ore studies is warranted to further elucidate these ﬁndings.
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